CXCR3 and type 1 diabetes mellitus: In the present study, the combination of ACT-777991, a new, potent, insurmountable, and selective small molecule CXCR3 antagonist [29], with aCD3 demonstrated superior efficacy over each monotherapy in persistently reverting diabetes in two different type 1 diabetes mouse models.